Revelation Biosciences REVB 深 沪
已收盘 02-06 16:00:00 美东时间
1.65
+0.180
+12.24%
华盛通- 最 高1.6694
- 今 开1.49
- 成交量 71.95万股
- 最 低 1.41
- 昨 收 1.47
- 总市值 244.37万
- 52周最高 54.48
- 市盈率 静 --
- 换手率 48.58%
- 52周最低 1.41
- 委 比 50.10%
- 总股本 148.10万
- 历史最高 2276064.00
- 量 比 1.47
- 振 幅 17.65%
- 历史最低 1.41
- 每 手 1
- 风险率 15.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01292026_REVB_Sorensen.pdf
01-29 23:14
Revelation Biosciences Announces 1-for-4 Reverse Stock Split
Revelation Biosciences Announces 1-for-4 Reverse Stock Split Revelation Biosciences Inc. announced a 1-for-4 reverse stock split of its common stock, effective January 28, 2026. The stock will begin trading on a post-split basis under the existing symbol "REVB" on that date. The reverse split aims t
01-26 22:55
Revelation Biosciences Raises $11 Million Through Immediate Warrant Exercise
Revelation Biosciences Raises $11 Million Through Immediate Warrant Exercise Revelation Biosciences Inc. has announced the immediate exercise of certain outstanding warrants, allowing holders to purchase up to 13,065,000 shares of common stock at a reduced exercise price of $0.86 per share. In conne
01-26 15:33
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its acute kidney injury treatment.
01-23 15:02
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers IO Biotech (NASDAQ:IOBT) stock increased by 76.7% to $0.37 during Thur...
01-23 01:05
Revelation Biosciences Reaches Agreement With FDA On Approval Pathway For Gemini To Treat Acute Kidney Injury
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced that the Company has reached agreement with the
01-21 21:33
Revelation Biosciences Starts GMP Production Of GEMINI, Placebo
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP manufacturing of GEMINI and
01-07 22:04
Revelation Biosciences Extends Stock Warrants Expiration
Revelation Biosciences ( ($REVB) ) has provided an announcement. On December 3,...
2025-12-04 06:28
Revelation Biosciences Announces The FDA Has Accepted Its End-Of-Phase 1 Meeting Package For Gemini, Its Acute Kidney Injury Treatment Candidate
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced successful submission and acceptance of the
2025-11-20 22:05
Revelation Biosciences Reschedules Stockholder Meeting
Revelation Biosciences ( ($REVB) ) has shared an update. On October 29, 2025, R...
2025-10-30 04:59
